Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany
European Journal of Clinical Microbiology & Infectious Diseases · 2024
DOI: 10.1007/s10096-024-04940-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Anne Wenzel und 4 weiteren Autor:innen. Beteiligte Einrichtung: VITIS Healthcare Group, Cologne, Germany. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Sepsis, Budgets. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noscendo GmbH, FOM Hochschule für Oekonomie und Management gGmbH.
Themen: Sepsis
Abstract (Originalsprache)
Purpose
Next-generation sequencing (NGS) tools have clinical advantages over blood culture but are more expensive. This study assesses the budget impact and break-even point of NGS testing costs from a healthcare provider’s perspective in Germany.
Methods
The budget impact was calculated based on aggregated data of German post-operative surgery cases. Simulated cost savings were calculated based on a simulated reduction in hospital length of stay (LOS) of four or eight days with a positivity rate of 71% and compared to the costs of one (scenario A) or two tests (scenario B) per case. Furthermore, the break-even point of the cost of two tests compared to saved costs through shortened LOS was conducted.
Results
For 9,450 cases, an average budget impact for scenario A and scenario B of €1,290.41 [95% CI €1,119.64 – €1,461.19] and - €208.59 [95% CI - €379.36 – - €37.81] was identified for gastrointestinal and kidney surgery cases, and €1,355.58 [95% CI €1,049.62 – €1,661.55] and €18.72 [95% CI - €324.69 – €287.24] for vascular artery surgery cases, respectively. The break-even analysis showed that using two tests per case could achieve a minimum positive contribution margin with an average of 1.9 tests per case across the study population.
Conclusion
The results revealed a positive budget impact for one NGS test and a slightly negative budget impact for two NGS tests per case. Findings suggest that largest cost savings are generated for more severe cases and are highly dependent on the patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- VITIS Healthcare Group, Cologne, Germany.
- Department of Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany.
- VITIS Healthcare Group, Cologne, Germany. florian.kron@fom.de.
- FOM University of Applied Sciences, Essen, Germany. florian.kron@fom.de.
Förderung
- Noscendo GmbH
- FOM Hochschule für Oekonomie und Management gGmbH
Zitieren
APA
Wenzel, A., Röder, J., Poos, T., Dusse, F., & Kron, F. (2024). Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04940-6
Vancouver
Wenzel A, Röder J, Poos T, Dusse F, Kron F. Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04940-6
BibTeX
@article{Wenzel2024,
author = {Wenzel, Anne and Röder, Johanna and Poos, Tabea and Dusse, Fabian and Kron, Florian},
title = {Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in Germany},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
doi = {10.1007/s10096-024-04940-6}
}
EUVIMED